Psychedelics 3.0: Challenges and Opportunities in an Evolving Field episode artwork

EPISODE · Oct 30, 2024 · 1H 2M

Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

from The Syneos Health Podcast · host Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing, Lindsay Crampton and Dr. Aaron Koenig

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications. Syneos Health experts Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing and Lindsay Crampton—along with Dr. Aaron Koenig, CMO of Delix Therapeutics—convened in a roundtable discussion to provide their own unique perspectives about the current and future state of psychedelic drug development and how to actively navigate the rapidly evolving field of clinical trials for these revolutionary treatments. Listen in to hear how psychedelics have progressed from their origins as a spiritual aid, their acceptance as a treatment for neuropsychiatric conditions, and the development of next-generation compounds. For more from our neuroscience experts, check out these insights: Syneos Health Podcast | Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?Artificial Intelligence and Alzheimer’s: Transforming Patient Screening with Predictive ModelsWEBINAR | Psychedelics 3.0: Challenges and OpportunitiesSyneos Health Podcast | World Mental Health Day: The State of Mental Health Clinical DevelopmentBLOG | The Reimbursement Case for Psychedelic Therapies Must Incorporate the Patient’s VoiceThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected]

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications. Syneos Health experts Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing and Lindsay Crampton—along with Dr. Aaron Koenig,...

NOW PLAYING

Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

0:00 1:02:37

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Syneos Health Podcast?

This episode is 1 hour and 2 minutes long.

When was this The Syneos Health Podcast episode published?

This episode was published on October 30, 2024.

What is this episode about?

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet...

Can I download this The Syneos Health Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!